Chr. Hansen's probiotic solution for pigs, BioPlus, celebrates 40 years on the market and still going strong. BioPlus 2B and BioPlus YC, Chr. Hansen's probiotic portfolio for pigs from farrow to finish, continues to be a strong solution in the farmers' tool box in their endeavor to obtain a more sustainable production based on natural solutions.
"We are very proud of celebrating this milestone with our customers around the world, who have seen, over the years, what BioPlus can do for their animals. Added to feed, our science-based products contain highly-selected strains of good bacteria that have been shown to support normal intestinal function. In addition, they improve the availability of absorbable nutrients from feed by producing digestive enzymes," says Mickaël Rouault, senior director, Commercial Development, Animal Health, Chr. Hansen.
"For the pig producer, this translates into a greater percentage of the herd showing normal performance, such as digestibility and feed efficiency, compared to groups that are not being fed BioPlus 2B or BioPlus YC – and it strengthens the sustainability profile because these advantages are obtained through natural means," says Chris Rhoden, manager, Business Development, Animal Health, Chr. Hansen.
These are trends that have only been reinforced since the first product (called Biomate at the time) was introduced in 1980.
"We have indeed witnessed that market trends are shifting towards more sustainable farming at pace with increasing consumer demand for animal welfare and natural products. At the same time, antibiotic resistance is recognized as a huge global challenge, and it is documented that probiotics can help support a normal gut function and may reduce the need for antibiotics," says Rouault.
At Chr. Hansen, 'good-bacteria' is at the heart of its business model, and are the first movers in innovation and technology when it comes to understanding the complexities of the probiotic modes of action and the gut microbiome – in animals as well as in humans. As such, product innovations stem from strong platforms in bioscience technologies and an in-depth understanding of the needs in the market. That is why the company calls its approach Science based, research proven.